文献速递肝病

不同遗传祖先的西班牙裔/拉丁裔人群中HSD17B13和PNPLA3与肝酶及纤维化的关联

Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-01-05

研究纳入8739名有基因分型和外显子测序数据的西班牙裔/拉丁裔成人,分析HSD17B13预测功能缺失变异和PNPLA3 I148M的患病率及其与肝酶和FIB-4评分的关联。厄瓜多尔和墨西哥血统者HSD17B13 pLoF频率最低(10%/7%)、PNPLA3 I148M频率最高(54%/65%),且转氨酶和FIB-4>2.67比例最高。HSD17B13 pLoF与ALT、AST、FIB-4降低相关,PNPLA3 I148M与三者升高相关,HSD17B13 pLoF可减轻PNPLA3 I148M所致的ALT升高。

要点

  • 厄瓜多尔和墨西哥血统者HSD17B13 pLoF频率最低(10%/7%),PNPLA3 I148M频率最高(54%/65%)。
  • HSD17B13 pLoF与ALT降低(P=.002)、AST降低(P<.001)、FIB-4降低(P=.045)相关。
  • PNPLA3 I148M与ALT、AST、FIB-4升高均相关(P<.001);HSD17B13 pLoF可减轻其ALT升高(P=.006)。

核心结论

  • HSD17B13和PNPLA3变异在不同遗传祖先群体中的分布差异可能促成西班牙裔/拉丁裔个体肝纤维化风险的不同。

研究设计与样本

  • 研究纳入纽约市BioMe生物样本库中8739名有基因分型和外显子测序数据的西班牙裔/拉丁裔成人,按遗传祖先分层估计变异患病率并做关联分析。

主要发现

  • 厄瓜多尔和墨西哥血统者HSD17B13 pLoF频率最低(10%/7%),PNPLA3 I148M频率最高(54%/65%),其门诊ALT、AST水平最高,FIB-4评分大于2.67的比例最大。
  • HSD17B13 pLoF变异与ALT降低(P=.002)、AST降低(P<.001)、FIB-4评分降低(P=.045)相关。
  • PNPLA3 I148M与ALT、AST、FIB-4评分升高均相关(P<.001)。
  • HSD17B13 pLoF变异减轻了PNPLA3 I148M所致的ALT升高(P=.006)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Genetic variants affecting liver disease risk vary among racial and ethnic groups. Hispanics/Latinos in the United States have a high prevalence of PNPLA3 I148M, which increases liver disease risk, and a low prevalence of HSD17B13 predicted loss-of-function (pLoF) variants, which reduce risk. Less is known about the prevalence of liver disease-associated variants among Hispanic/Latino subpopulations defined by country of origin and genetic ancestry. We evaluated the prevalence of HSD17B13 pLoF variants and PNPLA3 I148M, and their associations with quantitative liver phenotypes in Hispanic/Latino participants from an electronic health record-linked biobank in New York City. METHODS: This study included 8739 adult Hispanic/Latino participants of the BioMe biobank with genotyping and exome sequencing data. We estimated the prevalence of Hispanic/Latino individuals harboring HSD17B13 and PNPLA3 variants, stratified by genetic ancestry, and performed association analyses between variants and liver enzymes and Fibrosis-4 (FIB-4) scores. RESULTS: Individuals with ancestry from Ecuador and Mexico had the lowest frequency of HSD17B13 pLoF variants (10%/7%) and the highest frequency of PNPLA3 I148M (54%/65%). These ancestry groups had the highest outpatient alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and the largest proportion of individuals with a FIB-4 score greater than 2.67. HSD17B13 pLoF variants were associated with reduced ALT level (P = .002), AST level (P < .001), and FIB-4 score (P = .045). PNPLA3 I148M was associated with increased ALT level, AST level, and FIB-4 score (P < .001 for all). HSD17B13 pLoF variants mitigated the increase in ALT conferred by PNPLA3 I148M (P = .006). CONCLUSIONS: Variation in HSD17B13 and PNPLA3 variants across genetic ancestry groups may contribute to differential risk for liver fibrosis among Hispanic/Latino individuals.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rutledge SM, Soper ER, Ma N, et al. Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries. Clin Gastroenterol Hepatol. 2023. PMID: 36610497. doi:10.1016/j.cgh.2022.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。